MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Krystal Biotech Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

149.12 4.19

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

140.51

Max

150.11

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-9.7M

36M

Pardavimai

-3M

88M

P/E

Sektoriaus vid.

33.591

39.564

Pelno marža

40.521

Darbuotojai

275

EBITDA

-5.1M

38M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+36.31% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-08-04

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-763M

4B

Ankstesnė atidarymo kaina

144.93

Ankstesnė uždarymo kaina

149.12

Naujienos nuotaikos

By Acuity

49%

51%

154 / 376 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

Krystal Biotech Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-09 15:46; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250 Million Private Placement

2025-07-09 23:44; UTC

Rinkos pokalbiai

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 23:42; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

2025-07-09 22:59; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 20:26; UTC

Uždarbis

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

2025-07-09 19:18; UTC

Rinkos pokalbiai

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

2025-07-09 19:03; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

2025-07-09 18:31; UTC

Rinkos pokalbiai

Some Fed Officials Supported Considering July Cut -- Market Talk

2025-07-09 17:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk -2-

2025-07-09 16:20; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Health Care Roundup: Market Talk

2025-07-09 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-07-09 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-07-09 16:14; UTC

Rinkos pokalbiai

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

2025-07-09 16:14; UTC

Įsigijimai, susijungimai, perėmimai

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

2025-07-09 16:12; UTC

Rinkos pokalbiai

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

2025-07-09 16:08; UTC

Rinkos pokalbiai

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

2025-07-09 15:31; UTC

Pagrindinės rinkos jėgos

BitMine Shares Fall After Closing of $250M Private Placement

2025-07-09 15:31; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

2025-07-09 15:27; UTC

Rinkos pokalbiai

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

2025-07-09 14:36; UTC

Įsigijimai, susijungimai, perėmimai

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

2025-07-09 14:31; UTC

Įsigijimai, susijungimai, perėmimai

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

2025-07-09 14:26; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-07-09 14:26; UTC

Rinkos pokalbiai

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Akcijų palyginimas

Kainos pokytis

Krystal Biotech Inc Prognozė

Kainos tikslas

By TipRanks

36.31% į viršų

12 mėnesių prognozė

Vidutinis 195.38 USD  36.31%

Aukščiausias 240 USD

Žemiausias 155 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Krystal Biotech Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

9 ratings

8

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

133.221 / 169.73Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Very Strong Bearish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Rinkos nuotaikos

By Acuity

154 / 376 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.